Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris

February 2023 | Volume 22 | Issue 2 | 174 | Copyright © February 2023


Published online March 1, 2023

Adelaide A. Hebert MDa, Lawrence F. Eichenfield MDb, Diane Thiboutot MDc, Linda Stein Gold MDd, Snejina Vassileva MD PhDe, Yanita Mihaylova MDf, Martina Cartwright PhDg*h, Luigi Moro PhDi, Enrico Fragasso MSi*, Jenny Han MSj, Nicholas Squittieri MDk, Alessandro Mazzetti MDi

aThe UTHealth McGovern Medical School, Houston, TX
bUniversity of California, San Diego and Rady Children's Hospital, San Diego, CA
cDepartment of Dermatology, The Pennsylvania State University College of Medicine, Hershey, PA
dDepartment of Dermatology, Henry Ford Medical Center, Detroit, MI
eDepartment of Dermatology and Venereology, Medical University-Sofia, Sofia, Bulgaria
fAesthetic Club-Laser and Dermatological Clinic, Varna, Bulgaria
gCassiopea, Inc., San Diego, CA
hNovan Inc. Durham, NC
iCassiopea S.p.A., Lainate, Italy
jPharmapace Inc., San Diego, CA
kSun Pharmaceutical Industries, Inc., Princeton, NJ
*Employee at the time the work was conducted

REFERENCES

  1. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172( Suppl 1):3-12.
  2. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621-630.
  3. Kalabalik-Hoganson J, Frey KM, Ozdener-Poyraz AE, Slugocki M. Clascoterone: a novel topical androgen receptor inhibitor for the treatment of acne. Ann Pharmacother. 2021;55(10):1290-1296.
  4. Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241-248.
  5. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13-25.
  6. Eichenfield L, Hebert A, Gold LS, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477-485.
  7. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22(5):360-366.
  8. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005;141(3):333-338.
  9. Ceruti JM, Leirós GJ, Balañá ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122-133.
  10. Aizawa H, Nakada Y, Niimura M. Androgen status in adolescent women with acne vulgaris. J Dermatol. 1995;22(7):530-532.
  11. Winlevi® (clascoterone cream 1%). full prescribing information. Cassiopea inc. 2021.
  12. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973. e33.
  13. Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17α-propionate (Clascoterone) Is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412-418.
  14. Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197-201.
  15. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206(1):57-67.
  16. Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95(11):740-741.
  17. Ayatollahi A, Samadi A, Bahmanjahromi A, Robati RM. Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: a pilot study. Health Sci Rep. 2021;4(3):e317.
  18. Piszczatoski CR, Powell J. Topical clascoterone: the first novel agent for acne vulgaris in 40 years. Clin Ther. 2021;43(10):1638-1644.
  19. Santhosh P, George M. Clascoterone: a new topical anti-androgen for acne management. Int J Dermatol. 2021;60(12):1561-1565.
  20. Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, cb- 03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.
  21. Alkhodaidi ST, Al Hawsawi KA, Alkhudaidi IT, Magzoub D, Abu-Zaid A. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: a systematic review and meta-analysis of randomized placebo-controlled trials. Dermatol Ther. 2021;34(1):e14609.
Close Menu